When patients need class 1 clearance asap1,2

2 Week Dosing

Primary Efficacy Endpoint

2 Phase 3 Studies

45%
of patients were cleared or almost cleared of all signs of plaque psoriasis in 2 weeks1
~7x
more patients achieved treatment success with ULTRAVATE® Lotion (halobetasol propionate, 0.05%) vs vehicle lotion1

Secondary Efficacy Endpoint

Charts showing the percentage of patients achieving success

2 Phase 3 Studies

ULTRAVATE® Lotion demonstrated significant clearance of the signs and symptoms of plaque psoriasis in 2 weeks.1
The physical and social burden of plaque psoriasis can take the excitement out of upcoming events.

With ULTRAVATE® Lotion, clear or almost clear skin is possible in 2 weeks.1

See 2-Week Patient Results
References: 1. ULTRAVATE® Lotion [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2017. 2. Uva L, Miguel D, Pinheiro C, et al. Mechanisms of Action of Topical Corticosteroids in Psoriasis. International Journal of Endocrinology. https://doi.org/10.1155/2012/561018. November 20, 2012. Accessed December 9, 2020. 3. Pariser D, Bukhalo M, Guenthner S, et al. Two multicenter, randomized, double-blind, parallel group comparison studies of a novel enhanced lotion formulation of halobetasol propionate lotion, 0.05% versus its vehicle lotion in adult subjects with plaque psoriasis. J Drugs Dermatol. 2017;16(3):234-240.
INDICATIONS AND USAGE

ULTRAVATE (halobetasol propionate) Lotion is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION

Usage: Limit use to 50 g/week. Discontinue treatment when control is achieved. If no improvement is seen within 2 weeks, reassess diagnosis. Treatment beyond 2 consecutive weeks is not recommended. Avoid use on the face, scalp, groin, or axillae.

Effects on Endocrine System: Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, with the potential for glucocorticosteroid insufficiency during or after treatment. Systemic effects of topical corticosteroids may also include Cushing’s syndrome, hyperglycemia, and glucosuria. Systemic absorption may require evaluation for HPA axis suppression. Use of potent corticosteroids on large areas, for prolonged durations, under occlusive dressings, or on an altered skin barrier may increase systemic exposure. Children may be more susceptible to systemic toxicity when treated with topical steroids.

Local Adverse Reactions: Local adverse reactions with topical steroids may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection and miliaria. These may be more likely to occur with occlusive use, prolonged use or more potent corticosteroids, including ULTRAVATE.

Concomitant Skin Infections: Use an appropriate antimicrobial agent if a skin infection is present or develops.

Allergic Contact Dermatitis: Discontinue ULTRAVATE Lotion if allergic contact dermatitis is established.

In clinical trials the most common adverse reactions (≥1%) were telangiectasia, application site atrophy, and headache.

To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information for complete prescribing details.